CY1112702T1 - Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της - Google Patents

Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της

Info

Publication number
CY1112702T1
CY1112702T1 CY20121100385T CY121100385T CY1112702T1 CY 1112702 T1 CY1112702 T1 CY 1112702T1 CY 20121100385 T CY20121100385 T CY 20121100385T CY 121100385 T CY121100385 T CY 121100385T CY 1112702 T1 CY1112702 T1 CY 1112702T1
Authority
CY
Cyprus
Prior art keywords
pyrolidone
preparing
pharmaceutical composition
composition containing
improved pharmaceutical
Prior art date
Application number
CY20121100385T
Other languages
English (en)
Inventor
Evangelos Karavas
Efthimios Koutris
Dimitrios Bikiaris
Vicky Samara
Ioanna Koytri
Eleni Stathaki
Original Assignee
Pharmathen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen S.A. filed Critical Pharmathen S.A.
Publication of CY1112702T1 publication Critical patent/CY1112702T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία φαρμακευτική σύνθεση στερεών φαρμακοτεχνικών μορφών, η οποία περιλαμβάνει μία θεραπευτικά αποτελεσματική ποσότητα ενός αντισπασμωδικού παράγοντα πυρρολιδόνης, και ιδίως Λεβετιρακετάμης, ή ενός φαρμακευτικά αποδεκτού άλατος ή παραγώγου αυτής, σε συνδυασμό με ένα αποτελεσματικό αραιωτικό μέσο, όπως το Διβασικό Φωσφορικό Ασβέστιο, και πρόσθετα φαρμακευτικά έκδοχα, καθώς και μία διαδικασία για την παρασκευή αυτής με υγρή κοκκοποίηση.
CY20121100385T 2007-10-16 2012-04-25 Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της CY1112702T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2007/008952 WO2009049642A1 (en) 2007-10-16 2007-10-16 Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
EP07819022A EP2197428B1 (en) 2007-10-16 2007-10-16 Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof

Publications (1)

Publication Number Publication Date
CY1112702T1 true CY1112702T1 (el) 2016-02-10

Family

ID=39494325

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100385T CY1112702T1 (el) 2007-10-16 2012-04-25 Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της

Country Status (10)

Country Link
US (1) US8187635B2 (el)
EP (1) EP2197428B1 (el)
AT (1) ATE542525T1 (el)
CA (1) CA2696977C (el)
CY (1) CY1112702T1 (el)
DK (1) DK2197428T3 (el)
ES (1) ES2380010T3 (el)
PL (1) PL2197428T3 (el)
WO (1) WO2009049642A1 (el)
ZA (1) ZA201003380B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012008599A2 (pt) 2009-10-13 2019-09-24 Allostem Therapeutics Llc composto da formula (i), composto da fórmula (ia), composto da fórmula (ic), composto da fórmula (ii), composto da fórmula (iia), composto, método para tratamento de um transtorno hiperproliferativo em um mamífero, que inclui um humano, método para tratamento de uma doença, condição ou transtorno inflamatório em um mamífero, que inclui um humano, método para tratamento de um transtorno ou condição que é modulada pela cascata de meik em um mamífero, que inclui um himano, método para tratar ou prevenir câncer, composição farmacêutica e método para inibir uma enzima mek
US9333175B2 (en) * 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
AU2014228990B2 (en) 2013-03-15 2017-02-02 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
CN114206365A (zh) * 2019-08-06 2022-03-18 J·柯克兰 包含二氢和厚朴酚的制剂
CN114917195B (zh) * 2022-06-13 2024-06-11 河北戴桥医药科技有限公司 一种吡拉西坦片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
EP1558218A1 (en) * 2002-10-08 2005-08-03 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
US7132552B2 (en) * 2003-02-03 2006-11-07 Teva Pharmaceutical Industries, Ltd. Process for producing levetiracetam
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
AU2006228947A1 (en) * 2005-03-30 2006-10-05 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
EP1810676B1 (en) * 2006-01-24 2008-11-12 Teva Pharmaceutical Industries Limited Levetiracetam formulations and methods for their manufacture

Also Published As

Publication number Publication date
CA2696977A1 (en) 2009-04-23
EP2197428B1 (en) 2012-01-25
PL2197428T3 (pl) 2012-06-29
ATE542525T1 (de) 2012-02-15
DK2197428T3 (da) 2012-04-02
WO2009049642A1 (en) 2009-04-23
EP2197428A1 (en) 2010-06-23
US20110033538A1 (en) 2011-02-10
ZA201003380B (en) 2011-12-28
CA2696977C (en) 2012-12-04
US8187635B2 (en) 2012-05-29
ES2380010T3 (es) 2012-05-07

Similar Documents

Publication Publication Date Title
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
TN2010000022A1 (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
TW200612892A (en) Novel compounds
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2010111640A3 (en) Anti-influenza formulations and methods
MY146404A (en) Novel piperidine carboxylic acid amide derivatives
EP2548552A3 (en) Titration package for 1-amino-alkylcylohexanes
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
WO2009049648A3 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
ATE513820T1 (de) Neue benzamidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
WO2007025764A3 (de) Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel
ATE415151T1 (de) Formulierung zur verzögerten freisetzung von valproinsäure und deren derivate
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение
CY1108846T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει αναστολεα ace και μεθοδος για την παρασκευη της
WO2006129056A3 (en) Process and novel salt
EA200901205A1 (ru) Фармацевтическая композиция, содержащая соль розиглитазона
WO2010067989A3 (ko) 신규한 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2010027189A3 (ko) 호모아이소플라베논 또는 이의 염의 신규한 용도